Mangoceuticals Inc.
MGRX evidence brief
What we can confirm
- BioSniper Score:
- 6.6 / 10
- Market Cap:
- $8.7M
- Lead Asset:
- mango ed
What it means
What to watch
Prepared research question
What matters most for MGRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MGRX
Mangoceuticals Inc. (MGRX) is a biopharmaceutical company developing a patented respiratory illness prevention technology and a compounded erectile dysfunction product, currently in Phase II trials and facing ongoing net losses.
Key risk: Low cash runway
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$8.7M
Cash Runway
—
Lead Asset
mango ed
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Mangoceuticals Inc..
Mangoceuticals Inc. (MGRX) is a biopharmaceutical company developing a patented respiratory illness prevention technology and a compounded erectile dysfunction product, currently in Phase II trials and facing ongoing net losses.
- Cash & equivalents of $0.2M as of 2026-06-30 [sec]
- Total revenue of $0.1M as of 2026-06-30 [sec]
- Net income of -$1.3M as of 2026-06-30 [sec]
- Shareholders' equity of $12.5M as of 2026-06-30 [sec]
- Phase II clinical trials for patented respiratory illness prevention technology against influenza A (H1N1) and avian influenza (H5N1) were mostly completed in 2025 [sec_mda · as of 2026-08-13]
What works
- The company has a patented respiratory illness prevention technology that completed a majority of Phase II studies in 2025, targeting influenza A and H5N1 [sec_mda · as of 2026-08-13]
- Mangoceuticals reported zero respiratory-related mortality in approximately 29,000-bird commercial poultry field trials for its antiviral compound MGX-0024 [news · published 2026-02-23]
- The company holds a Master Distribution Agreement to license certain intellectual property and patent rights from Propre Energie, Inc. [sec_mda · as of 2026-08-13]
What to weigh
- The company has experienced recurring net losses since inception and expects to continue incurring substantial operating expenses [sec_mda · as of 2026-08-13]
- Cash decreased mainly due to funds used in operations with limited fundraising during the six-month period ended June 30, 2026 [sec_mda · as of 2026-08-13]
- As of June 30, 2026, total current liabilities were $1,398,063, including accounts payable and accrued liabilities of $889,733 [sec_mda · as of 2026-08-13]
- The company faces a competitive landscape for its erectile dysfunction product with 90 competitors, including Eli Lilly and Company and SK Chemicals Co., Ltd. [pipeline]
From the filings
Quoted directly from source documents.
Phase II clinical trials for respiratory illness prevention technology were mostly completed in 2025
“is in the process of conducting Phase II clinical trials and efficacy studies to determine the effectiveness of its patented respiratory illness prevention technology against the likes of the influenza A virus (H1N1) and avian influenza (H5N1). A majority of these studies were completed in 2025”
SEC MD&A · August 13, 2026
Zero respiratory-related mortality in poultry field trials for MGX-0024
“zero respiratory-related mortality in approximately 29,000-bird commercial poultry field trials in India and prophylactic benefits against H5N1 in a government-conducted challenge study”
News · February 23, 2026
Recurring net losses since inception
“experienced recurring net losses since inception”
SEC MD&A · August 13, 2026
Cash decreased due to operations with limited fundraising
“Cash decreased mainly due to funds used in operations with limited fundraising during the six-month period ended June 30, 2026”
SEC MD&A · August 13, 2026
Risks & what to watch (4)›
Key risks
- Low cash runway — Cash & equivalents of only $0.2M as of 2026-06-30 [sec]
- Recurring net losses — Net income of -$1.3M as of 2026-06-30 and recurring losses since inception [sec]
- Limited revenue — Total revenue of only $0.1M as of 2026-06-30 [sec]
- Competitive pressure — 90 competitors in erectile dysfunction market including major pharma [pipeline]
What to watch
- Next steps in commercialization and monetization of respiratory illness prevention technology after Phase II studies [sec_mda · as of 2026-08-13]
- Ability to raise additional funds given limited cash and ongoing operating expenses [sec_mda · as of 2026-08-13]
- Potential impact of government shutdown on FDA review or clinical trials [sec_mda · as of 2026-04-01]
Sources: News · Pipeline · SEC filings · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Mangoceuticals Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Mangoceuticals Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.13 · 0% dilution
No tracked pipeline phase
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of Apr 21, 2026- % of float
- 6.7%
- Days to cover
- 0.1
- Shares short
- 1,016,081
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MGRX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Mangoceuticals Inc.?
Mangoceuticals Inc. (MGRX) is a biopharmaceutical company developing a patented respiratory illness prevention technology and a compounded erectile dysfunction product, currently in Phase II trials and facing ongoing net losses.
Who is the CEO of Mangoceuticals Inc.?
Mr. Jacob D. Cohen is the chief executive officer of Mangoceuticals Inc. (MGRX).
Where is Mangoceuticals Inc. headquartered?
Mangoceuticals Inc. (MGRX) is headquartered in Dallas, TX, United States.
What therapeutic areas does Mangoceuticals Inc. focus on?
Mangoceuticals Inc. develops therapies across Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.